Ad Code: Vonjo - Myelofibrosis - Jul Display Banners HCP Wallboard Extension - 106831

Researchers at the 2024 ASCO Annual Meeting evaluated the performance of myelofibrosis prognostic models at an inner-city tertiary care center, characterized by diverse patient demographics, delayed disease presentation, and...

In a qualitative study, Anna Cardellino, MPH, and colleagues investigated the content validity of the Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0) in patients with myelofibrosis who had received JAK inhibitors....

Myelofibrosis is characterized by mutations in the JAK–STAT pathway, specifically in the myeloproliferative neoplasm (MPN) driver genes JAK2, CALR, and MPL. However, patients often have mutations in other MPN-related genes,...

T he selection process for transplant eligibility in myelofibrosis involves various factors such as age, dis – ease stage, comorbidities, performance status, and donor availability. Tools like the Myelofibrosis Transplant...